ALNY Alnylam Pharmaceuticals, Inc. Stock Quote

ALNY [NASD]

Index	-	P/E	-	EPS (ttm)	-7.83	Insider Own	0.30%	Shs Outstand	115.99M	Perf Week	13.43%
Market Cap	18.37B	Forward P/E	-	EPS next Y	-5.74	Insider Trans	-36.19%	Shs Float	115.24M	Perf Month	22.59%
Income	-890.90M	PEG	-	EPS next Q	-1.74	Inst Own	94.60%	Short Float	3.18%	Perf Quarter	15.58%
Sales	401.00M	P/S	45.81	EPS this Y	-7.00%	Inst Trans	0.08%	Short Ratio	6.03	Perf Half Y	5.05%
Book/sh	10.48	P/B	15.87	EPS next Y	19.60%	ROA	-31.40%	Target Price	164.04	Perf Year	39.40%
Cash/sh	16.61	P/C	10.02	EPS next 5Y	46.09%	ROE	-66.00%	52W Range	84.97 - 175.41	Perf YTD	28.00%
Dividend	-	P/FCF	-	EPS past 5Y	-10.80%	ROI	-65.40%	52W High	-5.16%	Beta	1.35
Dividend %	-	Quick Ratio	5.20	Sales past 5Y	34.20%	Gross Margin	83.20%	52W Low	95.79%	ATR	6.59
Employees	1323	Current Ratio	5.30	Sales Q/Q	79.60%	Oper. Margin	-	RSI (14)	72.57	Volatility	5.55% 4.30%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-13.80%	Profit Margin	-	Rel Volume	1.16	Prev Close	165.07
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 05 BMO	Payout	-	Avg Volume	607.78K	Price	166.36
Recom	2.00	SMA20	17.75%	SMA50	24.04%	SMA200	21.16%	Volume	704,310	Change	0.78%

Sep-30-20

Resumed

Berenberg

Hold

$145

Sep-08-20

Initiated

Citigroup

Buy

$170

Aug-11-20

Downgrade

Oppenheimer

Outperform → Perform

May-13-20

Initiated

RBC Capital Mkts

Sector Perform

$150

May-07-20

Downgrade

JP Morgan

Overweight → Neutral

$133 → $137

Apr-24-20

Resumed

Evercore ISI

Outperform

$160

Mar-19-20

Initiated

Berenberg

Buy

$200

Dec-19-19

Reiterated

Chardan Capital Markets

Buy

$150 → $190

Nov-20-19

Initiated

Oppenheimer

Outperform

$128

Nov-13-19

Initiated

BofA/Merrill

Buy

$110

May-23-19

Resumed

Goldman

Neutral

$80

Apr-12-19

Initiated

Evercore ISI

Outperform

Mar-06-19

Upgrade

Evercore ISI

In-line → Outperform

Mar-05-19

Upgrade

Morgan Stanley

Equal-Weight → Overweight

Jan-23-19

Initiated

UBS

Neutral

$87

Oct-01-18

Initiated

Cantor Fitzgerald

Overweight

$135

Aug-13-18

Reiterated

Stifel

Buy

$125 → $123

Aug-07-18

Upgrade

Stifel

Hold → Buy

$95 → $125

May-04-18

Reiterated

Stifel

Hold

$107 → $95

Mar-28-18

Initiated

Evercore ISI

In-line

Jan-11-21 04:29PM	Lilly Rockets On Alzheimer's News And 3 Other Highlights From Key Health Care Meeting Investor's Business Daily +6.80%
Jan-10-21 01:00PM	Alnylam Launches "Alnylam P5x25" Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years Business Wire
Jan-08-21 09:57AM	Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study Zacks +5.21%
Jan-07-21 07:00AM	Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Business Wire +9.91%
Jan-04-21 04:00PM	Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-21-20 11:37PM	Update: Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gained 52% In The Last Five Years Simply Wall St.
08:00AM	Alnylam Appoints Tolga Tanguler Chief Commercial Officer and Also Announces New CEMEA, Medical Affairs, and Compliance Leaders Business Wire
Dec-20-20 03:14PM	Is ALNY A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-17-20 04:21PM	12 Best Large Biotech Stocks to Buy Now Insider Monkey
Dec-15-20 07:00AM	Alnylam Announces 2021 Product and Pipeline Goals and Provides Program Updates at R&D Day Business Wire
Dec-14-20 03:51PM	Blackstones $3.45 Billion Deal For Lab Space Shows Boom in Life Sciences Barrons.com
Dec-08-20 08:00AM	Alnylam to Webcast Virtual R&D Day Business Wire
Dec-07-20 07:30AM	Alnylam Issues 2nd Annual Patient Access Philosophy Report Highlighting Broad Access to the Companys Approved Therapies Business Wire
Dec-05-20 11:31AM	Why Is Alnylam (ALNY) Down 6% Since Last Earnings Report? Zacks
Dec-04-20 11:06AM	Is The FDA Still Approving Drugs During the Pandemic? Motley Fool
08:45AM	Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study Zacks
Dec-03-20 01:52PM	PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels PR Newswire
08:07AM	Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO (lumasiran) PR Newswire
08:00AM	Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1 Business Wire
Nov-30-20 08:54AM	2 Biotech Funds Poised for a Healthy Breakout Investopedia
08:24AM	Reasons Alnylam Is a Top Biotech Stock to Buy Right Now Motley Fool
08:24AM	3 Reasons Alnylam Is a Top Biotech Stock to Buy Right Now Motley Fool
Nov-25-20 01:16PM	Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More Zacks
09:08AM	Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease Zacks
08:00AM	Alnylam to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference Business Wire
Nov-24-20 08:12AM	The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga
07:01AM	Alnylam Announces Innovative Value-Based Agreement Framework for OXLUMO (lumasiran) to Accelerate Access for Patients with Primary Hyperoxaluria Type 1 and Deliver Ultra-Rare Orphan Disease Pricing Solutions to U.S. Payers Business Wire
07:00AM	Alnylam Announces U.S. Food and Drug Administration (FDA) Approval of OXLUMO (lumasiran), the First and Only Treatment Approved for Primary Hyperoxaluria Type 1 to Lower Urinary Oxalate Levels in Pediatric and Adult Patients Business Wire
Nov-20-20 10:08AM	Alnylam (ALNY) Gets EU Nod for Oxlumo to Treat Renal Disease Zacks
Nov-19-20 07:00AM	Alnylam Receives Approval for OXLUMO (lumasiran) in the European Union for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups Business Wire
Nov-13-20 09:00AM	Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension Business Wire
Nov-07-20 07:24AM	Earnings Update: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts Simply Wall St.
Nov-06-20 10:48AM	Alnylam's (ALNY) Q3 Loss Wider Than Expected, Revenues Beat Zacks -5.17%
Nov-05-20 10:01PM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2020 Earnings Call Transcript Motley Fool
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Recent Period Activity Business Wire
Nov-04-20 08:30AM	Is a Surprise Coming for Alnylam (ALNY) This Earnings Season? Zacks +8.09%
Nov-03-20 01:14PM	Were These Hedge Funds Wrong About Alnylam Pharmaceuticals, Inc. (ALNY)? Insider Monkey
Nov-02-20 04:00PM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences Business Wire
Oct-31-20 08:00AM	Kaskela Law LLC Announces Stockholder Investigation of Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
Oct-30-20 07:00AM	Alnylam Wins Prestigious Prix Galien Award for Best Biotechnology Product with First-Ever Approved RNAi Therapeutic, ONPATTRO® (patisiran) Business Wire
Oct-29-20 03:06PM	Alnylam Named a Top Biopharma Employer by Science Magazine Business Wire
12:35PM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-22-20 04:00PM	Alnylam to Webcast Conference Call Discussing Third Quarter 2020 Financial Results Business Wire
12:33PM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy? Zacks
10:00AM	Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week Business Wire
Oct-19-20 12:46PM	Is Ionis Pharmaceuticals a Buy? Motley Fool
09:55AM	Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran Zacks
Oct-18-20 06:43AM	Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus? Motley Fool
Oct-16-20 06:00AM	Alnylam Receives Positive CHMP Opinion for OXLUMO (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 in All Age Groups Business Wire
Oct-15-20 04:12PM	Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment Investor's Business Daily
Oct-11-20 08:33AM	When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Turn A Profit? Simply Wall St.
Oct-01-20 10:50AM	Alnylam Releases Positive Top-Line Rare Disease Lumasiran Data Zacks
Sep-30-20 04:19PM	Alnylam Pharmaceuticals Posts Positive Results For Its Treatment For Rare Disease Investor's Business Daily
07:00AM	Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six Business Wire
Sep-28-20 04:00PM	Alnylam to Webcast Presentation at Chardan Virtual 4th Annual Genetic Medicines Conference Business Wire
Sep-16-20 04:24PM	Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps Investor's Business Daily
Sep-09-20 09:47PM	Hedge Funds Have Never Been This Bullish On Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
06:29AM	3 Healthcare Stocks I Can't Wait to Buy When the Stock Market Tanks Again Motley Fool
Sep-05-20 11:32AM	Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report? Zacks
Sep-04-20 06:35PM	Analyst Report: Alnylam Pharmaceuticals, Inc. Morningstar Research
Sep-03-20 07:30AM	Alnylam Highlights Prospects for Building an Industry-Leading ATTR Amyloidosis Franchise at RNAi Roundtable Business Wire
Sep-02-20 08:00AM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences Business Wire
Aug-27-20 10:17AM	Alnylam's Share Price Rises YTD on Pipeline Developments Zacks
08:13AM	Here's What We Learned About The CEO Pay At Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Simply Wall St.
Aug-17-20 07:30AM	Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease Business Wire
Aug-07-20 10:56AM	Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance Zacks
Aug-06-20 11:25AM	Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity Business Wire
07:30AM	Alnylam Announces Planned Transition of Barry Greene, President Business Wire
Aug-03-20 07:30AM	Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) Business Wire
Jul-30-20 12:33PM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-23-20 11:02AM	A Top Contender in the Race for a NASH Drug Drops Out Barrons.com
08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results Business Wire
Jul-14-20 12:00PM	Alnylam (ALNY) Upgraded to Buy: Here's Why Zacks
Jul-13-20 10:45AM	Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 34%? Simply Wall St. -5.86%
07:28AM	Alnylam Announces that the United Kingdoms MHRA Grants Early Access to Lumasiran Business Wire
Jul-09-20 08:54PM	Did Hedge Funds Make The Right Call On Alnylam Pharmaceuticals, Inc. (ALNY) ? Insider Monkey
Jul-08-20 07:57AM	Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States Business Wire
Jul-01-20 11:48AM	Alnylam Pharma Poised to Shoot Higher TheStreet.com
07:00AM	FOCUS-From Parkinson's to peanut allergy, pandemic puts brakes on new drugs Reuters
Jun-30-20 09:00AM	Alnylam Reports New 12-Month Interim Data From the ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria Business Wire
Jun-28-20 04:51PM	New Pharma ETF Focuses on Testing and Treatment for Infectious Diseases--but Not Covid-19 GuruFocus.com
Jun-18-20 07:00AM	Alnylam to Host Seventh Annual "RNAi Roundtable" Webcast Series Business Wire
Jun-17-20 04:00PM	Alnylam to Webcast Presentation at Bank of America Securities 2020 Napa Biopharma Conference Business Wire
09:50AM	Alnylam???s Share Price Rises YTD on Pipeline Developments Zacks
Jun-10-20 05:07PM	Alnylam Announces Publication of ENVISION Phase 3 Study Results for Givosiran in the New England Journal of Medicine Business Wire
Jun-08-20 10:00AM	Alnylam Reports Positive Phase III Results on Lumasarin Zacks
09:00AM	Pfizer Is Charging Ahead With A Coronavirus Vaccine Is PFE Stock A Buy? Investor's Business Daily
03:24AM	Alnylam Reveals Solid Lumasiran Results; Analyst Says Dicerna Better Pick SmarterAnalyst
Jun-07-20 07:15AM	Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1 Business Wire
Jun-05-20 11:32AM	Why Is Alnylam (ALNY) Down 6.8% Since Last Earnings Report? Zacks
Jun-04-20 03:54PM	Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Getting Bullish Insider Monkey
Jun-02-20 08:00AM	Alnylam Announces Recipients of Second Annual Advocacy for Impact Grants Program Business Wire
Jun-01-20 07:00AM	Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress Business Wire
May-27-20 09:47AM	Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA Zacks
May-26-20 04:00PM	Alnylam to Webcast Presentations at Upcoming June Investor Conferences Business Wire
07:00AM	Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT Thomson Reuters StreetEvents
07:00AM	Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1 Business Wire
May-25-20 11:30AM	Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? Zacks
May-22-20 12:30PM	Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020 Business Wire

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KEATING LAURIE	EVP, Chief Legal Officer	Jan 13	Option Exercise	82.45	9,027	744,290	11,261	Jan 15 04:03 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 13	Sale	169.90	9,027	1,533,698	2,234	Jan 15 04:03 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 12	Option Exercise	72.83	14,941	1,088,149	17,175	Jan 13 04:05 PM
Greenstreet Yvonne	President & COO	Jan 12	Option Exercise	42.22	3,125	131,938	7,945	Jan 13 04:04 PM
Greenstreet Yvonne	President & COO	Jan 12	Sale	161.00	3,125	503,125	4,820	Jan 13 04:04 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 12	Sale	160.20	14,941	2,393,619	2,234	Jan 13 04:05 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 11	Sale	154.00	758	116,732	2,234	Jan 13 04:05 PM
PAUL STEVEN M	Director	Dec 18	Option Exercise	9.30	15,000	139,500	16,000	Dec 22 04:02 PM
PAUL STEVEN M	Director	Dec 18	Sale	140.00	15,000	2,100,000	1,000	Dec 22 04:02 PM
SHARP PHILLIP A	Director	Nov 25	Option Exercise	9.30	30,000	279,000	265,633	Nov 30 04:03 PM
SHARP PHILLIP A	Director	Nov 25	Sale	124.89	30,000	3,746,749	235,633	Nov 30 04:03 PM
MARAGANORE JOHN	Chief Executive Officer	Nov 19	Option Exercise	9.14	34,765	317,752	232,354	Nov 20 04:02 PM
MARAGANORE JOHN	Chief Executive Officer	Nov 19	Sale	124.23	34,765	4,319,025	197,589	Nov 20 04:02 PM
Vaishnaw Akshay	President, R&D	Sep 29	Option Exercise	42.22	971	40,996	15,090	Oct 01 04:03 PM
Vaishnaw Akshay	President, R&D	Sep 29	Sale	140.00	971	135,940	14,119	Oct 01 04:03 PM
Greene Barry E	President	Sep 09	Option Exercise	9.14	44,530	407,004	114,873	Sep 11 05:11 PM
Greene Barry E	President	Sep 09	Sale	123.23	44,530	5,487,594	70,343	Sep 11 05:11 PM
MARAGANORE JOHN	Chief Executive Officer	Aug 20	Option Exercise	9.14	34,765	317,752	232,354	Aug 21 04:06 PM
MARAGANORE JOHN	Chief Executive Officer	Aug 20	Sale	136.13	34,765	4,732,542	197,589	Aug 21 04:06 PM
Greene Barry E	President	Aug 10	Option Exercise	70.95	4,931	349,871	67,167	Aug 11 04:09 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jul 13	Option Exercise	87.16	35,750	3,116,066	50,242	Jul 14 04:03 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jul 13	Sale	160.67	47,250	7,591,790	2,992	Jul 14 04:03 PM
Greenstreet Yvonne	Chief Operating Officer	Jul 10	Option Exercise	77.10	46,639	3,595,867	51,459	Jul 14 04:02 PM
Greenstreet Yvonne	Chief Operating Officer	Jul 10	Sale	161.00	46,639	7,508,879	4,820	Jul 14 04:02 PM
Greenstreet Yvonne	Chief Operating Officer	Jul 09	Option Exercise	43.14	11,236	484,743	16,056	Jul 10 04:03 PM
Greenstreet Yvonne	Chief Operating Officer	Jul 09	Sale	161.00	11,236	1,808,996	4,820	Jul 10 04:03 PM
Greene Barry E	President	Jul 07	Option Exercise	9.14	22,265	203,502	84,501	Jul 09 04:02 PM
Greene Barry E	President	Jul 07	Sale	159.99	22,265	3,562,177	62,236	Jul 09 04:02 PM
Vaishnaw Akshay	President, R&D	Jun 22	Option Exercise	42.22	970	40,953	15,089	Jun 24 04:02 PM
Vaishnaw Akshay	President, R&D	Jun 22	Sale	151.07	970	146,536	14,119	Jun 24 04:02 PM
MARAGANORE JOHN	Chief Executive Officer	May 20	Option Exercise	9.14	34,765	317,752	232,354	May 22 04:03 PM
MARAGANORE JOHN	Chief Executive Officer	May 20	Sale	143.22	34,765	4,978,983	197,589	May 22 04:03 PM
Greenstreet Yvonne	Chief Operating Officer	May 06	Option Exercise	77.10	50,000	3,855,000	54,820	May 07 04:08 PM
Greene Barry E	President	May 06	Option Exercise	9.14	22,265	203,502	84,501	May 07 04:09 PM
Greenstreet Yvonne	Chief Operating Officer	May 06	Sale	150.00	50,000	7,500,000	4,820	May 07 04:08 PM
Greene Barry E	President	May 06	Sale	149.99	22,265	3,339,527	62,236	May 07 04:09 PM
Greenstreet Yvonne	Chief Operating Officer	May 05	Option Exercise	42.22	7,811	329,780	12,631	May 07 04:08 PM
Greenstreet Yvonne	Chief Operating Officer	May 05	Sale	140.00	7,811	1,093,540	4,820	May 07 04:08 PM
KEATING LAURIE	EVP, Chief Legal Officer	Apr 20	Option Exercise	77.40	10,000	774,000	24,492	Apr 22 04:07 PM
Vaishnaw Akshay	President, R&D	Apr 20	Option Exercise	42.22	21,971	927,616	36,090	Apr 22 04:06 PM
Vaishnaw Akshay	President, R&D	Apr 20	Sale	140.00	21,971	3,075,940	14,119	Apr 22 04:06 PM
KEATING LAURIE	EVP, Chief Legal Officer	Apr 20	Sale	139.00	10,000	1,390,000	14,492	Apr 22 04:07 PM
MARAGANORE JOHN	Chief Executive Officer	Feb 20	Option Exercise	9.14	34,765	317,752	224,758	Feb 21 04:02 PM
MARAGANORE JOHN	Chief Executive Officer	Feb 20	Sale	131.85	34,765	4,583,674	189,993	Feb 21 04:02 PM
SHARP PHILLIP A	Director	Feb 12	Option Exercise	12.48	30,000	374,400	265,633	Feb 13 04:06 PM
SHARP PHILLIP A	Director	Feb 12	Sale	130.00	30,000	3,900,000	235,633	Feb 13 04:06 PM
KEATING LAURIE	EVP, Chief Legal Officer	Feb 10	Option Exercise	77.40	10,000	774,000	22,258	Feb 12 04:03 PM
Greenstreet Yvonne	Chief Operating Officer	Feb 10	Option Exercise	42.22	5,600	236,432	11,808	Feb 11 04:08 PM
PAUL STEVEN M	Director	Feb 10	Option Exercise	14.67	30,000	440,100	31,000	Feb 11 04:08 PM
PAUL STEVEN M	Director	Feb 10	Sale	130.00	30,000	3,900,000	1,000	Feb 11 04:08 PM
KEATING LAURIE	EVP, Chief Legal Officer	Feb 10	Sale	129.00	10,000	1,290,000	12,258	Feb 12 04:03 PM
Greenstreet Yvonne	Chief Operating Officer	Feb 10	Sale	130.00	9,892	1,285,960	1,916	Feb 11 04:08 PM
Vaishnaw Akshay	President, R&D	Feb 07	Option Exercise	42.22	22,750	960,505	34,923	Feb 11 04:08 PM
Greenstreet Yvonne	Chief Operating Officer	Feb 07	Option Exercise	42.22	6,250	263,875	12,458	Feb 11 04:08 PM
Greenstreet Yvonne	Chief Operating Officer	Feb 07	Sale	123.90	6,250	774,375	6,208	Feb 11 04:08 PM
Vaishnaw Akshay	President, R&D	Feb 07	Sale	125.00	23,708	2,963,500	11,215	Feb 11 04:08 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 29	Option Exercise	77.40	6,337	490,484	14,932	Jan 31 04:05 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 29	Sale	119.00	6,337	754,103	8,595	Jan 31 04:05 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 27	Option Exercise	42.22	34,374	1,451,270	49,632	Jan 29 04:03 PM
KEATING LAURIE	EVP, Chief Legal Officer	Jan 27	Sale	117.70	41,037	4,829,970	8,595	Jan 29 04:03 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience